Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moratorium pushes Glenmark to new Indian site for Napo's crofelemer

This article was originally published in Scrip

Executive Summary

A Indian government-imposed temporary moratorium on new projects in Ankleshwar is said to have forced Glenmark to consider an alternative site in Aurangabad for manufacturing the active pharmaceutical ingredient (API) for Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer. However, the company says that the moratorium is a general one and nothing to do with any of Glenmark's specific processes or plants.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel